



## Charles River Announces New and Continued Drug Discovery Collaborations

October 7, 2015

*Wellcome Trust-Funded Projects Expand Partnerships with Charles River's Global Discovery Services Business*

WILMINGTON, Mass.--(BUSINESS WIRE)--Oct. 7, 2015-- [Charles River Laboratories International, Inc.](#) (NYSE: [CRL](#)) today announced new and continuing collaborations with three innovative drug discovery partners funded by the Wellcome Trust. Antabio, an anti-bacterial drug discovery company, Pcovery, a spin-out company focused on anti-fungals, and the British Columbia Cancer Agency have all extended existing or commenced new agreements with Charles River's Global Discovery Services business.

"We are delighted Antabio, Pcovery, and the British Columbia Cancer Agency selected Charles River as their partner for the Wellcome Trust's Seeding Drug Discovery (SDD) funded programs," said Emily Hickey, Corporate Senior Vice President, Global Discovery Services, Charles River. "We look forward to supporting these organizations in their goal to identify new therapies to treat—and hopefully cure — diseases."

As part of the agreements, Charles River's Discovery Business will provide a comprehensive suite of *in vitro* and *in vivo* pharmacology, drug metabolism and pharmacokinetics (DMPK), and medicinal chemistry services, which are outlined below:

- For the **British Columbia Cancer Agency**, Charles River will begin a new project providing chemistry/computer-aided drug design (CADD), biochemical and cell assays, and *in vitro* and *in vivo* DMPK studies to improve radiotherapy treatments for cancer.
- For **Antabio**, Charles River will begin a new project developing a novel drug for infections in cystic fibrosis patients with project management, CADD, and medicinal and synthetic chemistry input. Charles River will also continue providing Antabio with medicinal and synthetic chemistry, CADD, and *in vitro* and *in vivo* DMPK services to develop drug candidates that inhibit antibiotic resistance.
- For **Pcovery**, Charles River will continue providing CADD and medicinal and synthetic chemistry support to develop antifungal treatments with the potential to destroy otherwise drug-resistant fungi.

For each project, the Charles River Discovery team worked closely with its respective partners, providing scientific support and insight into the development of the grant applications, and the generation and delivery of scientific presentations to the Wellcome Trust Scientific Advisory Board prior to project initiation.

### About the Wellcome Trust

The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust's breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests. [www.wellcome.ac.uk](http://www.wellcome.ac.uk)

### About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit [www.criver.com](http://www.criver.com).

For more information visit [www.criver.com](http://www.criver.com)

View source version on businesswire.com: <http://www.businesswire.com/news/home/20151007005064/en/>

Source: Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc.

Investor Contact:

Susan E. Hardy, 781-222-6190

Corporate Vice President, Investor Relations

[susan.hardy@crl.com](mailto:susan.hardy@crl.com)

or

Media Contact:

Amy Cianciaruso, 781-222-6168

Executive Director, Public Relations

[amy.cianciaruso@crl.com](mailto:amy.cianciaruso@crl.com)